# Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

> **NCT00674648** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** CMV-Peptide-Specific T cells

## Key facts

- **NCT ID:** NCT00674648
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674648, "Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00674648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*